CRISPR Therapeutics (CRSP) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Portfolio and financial highlights

• CASGEVY launch is progressing well, with over $100 million in revenues expected in 2025 and significant growth projected for 2026, supported by nearly 300 patients initiating treatment.

• The company remains well capitalized with $1.94 billion on the balance sheet, supporting execution across its pipeline.

• Anticipates 2025 as a peak spending year, with profitability for the franchise expected by 2028 as revenues increase and costs stabilize.

Pipeline progress and clinical updates

• CTX310 program targeting ANGPTL3 demonstrated 55% reduction in triglycerides and 50% reduction in LDL, with strong KOL support.

• Cell therapy updates are expected by year-end, including initial autoimmune data for CTX112 and additional oncology data in aggressive lymphomas.

• Factor XI program is advancing, with a key TKA study readout anticipated in the second half of 2026.

• Lp(a) program (CTX320) is ongoing, with development strategy to be informed by the upcoming Horizon trial results.

Competitive positioning and differentiation

• Factor XI program aims to address unmet needs in stroke prevention, AF, and cancer-associated thrombosis, offering potent clot inhibition with limited bleeding risk and a differentiated durability and reversibility profile.

• The siRNA approach allows for single-shot therapy with prolonged activity and the ability to reverse effects if needed, setting it apart from biologics and orals.

• The company benefits from observing earlier entrants in the Factor XI space, allowing benchmarking on both efficacy and pricing.